Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Reformulated Dalpiciclib in Healthy Volunteers
NCT04301804Phase 1Completed
- Sponsor
- Atridia Pty Ltd
- Start
- Mar 2020
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dalpiciclib in breast cancer (3 arms), sponsored by Atridia Pty Ltd. Primary endpoints: Number of subjects with laboratory tests findings of potential clinical importance up to 1 year, Number of subjects with adverse events (AEs) up to 1 year and 1 more. Started Mar 2020; status: completed.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04301804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04301804.